Section 3 of 6
Product information and disease description
274 evidence topics · 130 sources
Product description
Phase of product development
Investigational status and current development phase
Regulatory status: Submission planned; U.S. and EU filings planned on ARCHER II results, timing not announced
Launch
No evidence found.
FDA alignment on best-corrected visual acuity loss as the primary outcome measure
FDA Fast Track designation for geographic atrophy
EMA Priority Medicine (PRIME) designation
EMA Product Development Coordinator pilot
Month 24 dual primary endpoint and open-label extension added in August 2026
Regulatory risk stated by the sponsor for the amended design
ARROW head-to-head trial against pegcetacoplan: planned in 2023
ARROW head-to-head trial against pegcetacoplan: no longer planned as of March 2025
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Annexon Biosciences
International nonproprietary name: recommended INN
Therapeutic class: antigen-binding fragment inhibiting C1q
Brand name
No evidence found.
Dosage forms and strengths
Dosage form in phase 3: solution for intravitreal injection
Molecule and dose volume in ARCHER II: 5 mg in 25 microliters
Expression system and glycosylation
Doses and injection volumes in the phase 1 glaucoma studies
Concentration, commercial presentation, packaging, and storage
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
WHO INN functional classification of vonaprument
WHO ATC classification of the approved complement inhibitors for geographic atrophy (S01XA)
AHFS classification and ATC code for vonaprument
No evidence found.
Indication
Indication under development as stated by the sponsor
Indication as registered for the phase 3 trial
Label claim sought by the sponsor: protection of vision
Population targeted in ARCHER II: participants with enough vision to protect
Other indications studied: glaucoma (phase 1, supporting development in GA)
Pharmacology
Mechanism of action
Antigen-binding fragment that selectively inhibits C1q
Nonproprietary name description: anti-C1q globular head region Fab
Binding to the substrate-binding head groups of C1q
“ANX007 is a novel high affinity monoclonal antibody antigen-binding fragment (Fab) that was designed to specifically recognize the substrate-binding head groups of C1q to functionally inhibit the classical complement cascade.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The blockade of C1q prevents recruitment and activation of all downstream components within the classical pathway, including C4, C3, and C5, that drive a local immune response and tissue destruction in the retina.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Binding affinity and preservation of the lectin and alternative pathways
“ANX007 is an investigational, humanized antibody antigen-binding fragment that recognizes C1q and blocks its initiation of the classical complement pathway” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By selectively targeting C1q, ANX007 inhibits the classical pathway while leaving the lectin and alternative complement pathways intact for normal immune function and tissue homeostasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ANX007 exhibits binding affinity for C1q (KD = 10 pM) and is a potent inhibitor of the classical complement cascade.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Product profile: 50 kD non-pegylated Fab with the anti-C1q structure of tanruprubart
“Modeled on established IVT Fab antibodies” (opens the source at this quote in a new tab)
“Same anti-C1q structure as tanruprubart” (opens the source at this quote in a new tab)
“Small 50 kD Fab antibody” (opens the source at this quote in a new tab)
“Full target engagement of classical pathway” (opens the source at this quote in a new tab)
Rationale for local C1q inhibition in geographic atrophy
Proposed differences from C3 and C5 inhibition
“However, C3 and C5 inhibitors block the central and terminal aspects of all three complement pathways.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, preventing the focused binding of C1q to its substrates would block all downstream classical cascade components and their amplification to reduce overall complement activation, while leaving the clearance and tissue repair functions of the lectin and alternative complement pathways in place.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Aqueous humor C1q target engagement: phase Ib glaucoma study
“Correspondingly, mean (SD) and median (min, max) unbound C1q at day 1 (preinjection) was 100.1 (99.9) and 51.6 (16, 254) ng/ml in sham, 110.0 (109.5) and 65.7 (23, 293) in the ANX007 2.5 mg dose group, and 110.0 (83.1) and 86.8 (14, 222) in the ANX007 5.0 mg dose groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unbound C1q was reduced to undetectable levels at day 29 (< 0.6 ng/ml) in aqueous humor at both dose levels in all subjects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Full engagement of C1q in the aqueous humor at day 29 in all treated subjects supports monthly or less-frequent dosing of ANX007 in future clinical studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum C1q after intravitreal dosing: phase Ia glaucoma study
Dose selection for monthly intravitreal injection
In vitro binding and complement pathway selectivity
“The binding affinity of ANX007 to purified human C1q and to C1q captured from human and cynomolgus monkey serum were similar, with EC50 values of 136 pM (7.7 ng/mL), 147 pM (8 ng/mL), and 179 pM (9.5 ng/mL), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ANX007 specifically inhibited classical complement-mediated activation at 6 nM (300 ng/mL) and had no effect on the lectin or the alternative pathway” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ocular target engagement in nonhuman primates
“In contrast, suppression of free-C1q levels was maintained at days 44 and 59 in all tissues except the optic nerve.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C1q inhibition was near complete in all samples at day 44, approximately 2 weeks after the second dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results demonstrate that aqueous humor C1q target engagement is reflected in C1q lowering in both vitreous and the retina.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, in clinical studies where vitreous and ocular tissues cannot be sampled, these data support the relevance of aqueous humor target engagement as a surrogate for retinal target engagement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical pharmacology: photo-oxidative photoreceptor damage model
Preclinical pharmacology: intravitreal and systemic anti-C1q in a light damage model
“Genetic deletion or pharmacological inhibition of C1q provided protection against photoreceptor cell loss and preserved receptor cell function, even when inhibition was provided after damage had occurred” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, while local (intravitreal) administration of an anti-C1q antibody was protective, systemic administration was not—presumably due to local production of C1q in the retina and to lower levels of antibody penetration into the eye with systemic dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical pharmacology: microglia, synapses, and photoreceptors after light-induced damage
Pharmacokinetics
Aqueous humor concentrations: phase Ib glaucoma study
“Mean (SD) and median (min, max) ANX007 levels in aqueous humor on day 29 were 911 ng/ml (846) and 631 (225, 2539) ng/ml in the ANX007 2.5 mg dose group and 5345 ng/ml (6351)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose-dependent increase in aqueous unbound ANX007 levels 29 days after a single intravitreal dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum concentrations: phase Ia glaucoma study
“The method for the quantitative determination of unbound ANX007 in human serum used an electrochemiluminescence immunoassay with a quantification range of 1.25 ng/ml to 250.0 ng/ml, run at a minimum required dilution of 40-fold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serum unbound ANX007 was not detected” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vitreous half-life in humans
No evidence found.
Vitreous half-life and aqueous-to-vitreous ratio in nonhuman primates
“The ANX007 half-life was approximately 3 days in the vitreous humor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Aqueous and vitreous levels were highly correlated, and aqueous levels of free-ANX007 were approximately four-fold lower than in the vitreous” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The half-life of ANX007 in the vitreous following IVT administration was approximately 3 days, which is consistent with published data for other humanized monoclonal antibody fragments administered through this route” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single-dose toxicokinetics in nonhuman primates
Ocular tissue distribution after repeat dosing in nonhuman primates
“At day 59 (approximately 4 weeks post-last dose), free-ANX007 persisted in vitreous and aqueous humor but not in the optic nerve, choroid, or retina.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data indicate that binding of ANX007 to C1q persists to 59 days in all tissues but the optic nerve, and that ANX007 was able to access the back of the eye” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although free-Fab was no longer detected, C1q was still bound to ANX007 and thus fully inhibited in the choroid at day 59 (approximately 4 weeks post-last dose).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity: phase I glaucoma studies
“No ADAs positivity was detected during the study at any ANX007 dose level at any of the timepoints assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Low levels of ADA positivity were detected in 7 patients (1 patient in the sham group, 3 patients in the ANX007 2.5 mg group, and 3 patients in the ANX007 5 mg group).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These patients likely represent false positives in the ADA assay, as there was no change in titer over time and ADA positivity was detected before dosing in the ANX007 groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity and systemic exposure in nonhuman primates
“The generation of anti-drug antibody (ADA) was assessed in a validated assay in the repeat dose 5 mg/eye study, and 9 of the 10 treated animals were ADA positive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the effects of ADA on the toxicokinetics of ANX007 were not included in the toxicokinetic evaluation due to the low and transient systemic exposure of ANX007 in serum” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Age range studied: ARCHER II
Age range studied: ARCHER
Age range studied: phase I glaucoma studies
“In the phase Ia study, eligible patients were aged ≥ 18 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the phase Ib study, eligible patients were aged ≥ 18 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean age overall was 70 years in phase Ia and 68 years in phase Ib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age of enrolled participants: ARCHER and ARCHER II
| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
|---|---|---|
| Age, mean (SD) | “80.0 (8.2)” | “78.4 (8.0)” |
Pregnancy, breastfeeding, and contraception: ARCHER eligibility criterion
Pediatric use, renal impairment, and hepatic impairment
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on Vonaprument
Clinical drug interaction studies
No evidence found.
Prior intravitreal treatment excluded in ARCHER
Concomitant glucocorticoids excluded in the phase Ib glaucoma study
Effects of Vonaprument on other drugs
Clinical drug interaction studies
No evidence found.
Systemic exposure after intravitreal administration as context for interaction potential
Dosing and administration
Dosage
ARCHER II: 5.0 mg per eye monthly for 24 months
ARCHER: 5 mg monthly or every other month for 12 months
Open-label extension: monthly dosing for 24 months
Dose selection: aqueous humor target engagement in phase 1
Proposed labeled dose, dosing interval, and dose modification
No evidence found.
Administration
Route: intravitreal injection
Injection procedure in the phase 1 glaucoma studies
“Intravitreal injection was performed under sterile conditions. Topical proparacaine was used for anesthesia. Lid margins were cleaned with Povidone-iodine 10% and povidone-iodine 5% was applied to the conjunctival surface, including the injection site.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For ANX007 injection, the needle was inserted perpendicular to the sclera, 3.5 to 4 mm posterior to the limbus, between the vertical and horizontal rectus muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intraocular pressure was checked postinjection. Topical antibiotics were not used postinjection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Needle gauge, delivery device, and post-injection monitoring instructions for the commercial product
No evidence found.
Access and distribution
Current access through clinical trials and the open-label extension
Manufacturing: contract manufacturers in Europe
Commercial supply and technology transfer
Commercial organization and distribution capabilities
Patent protection
Expanded access program, HCPCS code, distribution channel, and REMS
No evidence found.
Co-prescribed/Concomitant therapies
ARCHER: prior intravitreal and AMD treatments excluded, oral supplements permitted
ARCHER: procedures affecting drug distribution
ARCHER II: concomitant and prior therapy criteria
No evidence found.
Use with pegcetacoplan or avacincaptad pegol
No evidence found.
Effect of Vonaprument on quality measures
MIPS Quality ID 14: AMD dilated macular examination, 2023 specification
Removal of MIPS Quality ID 14 for the 2024 performance year
IRIS Registry QCDR measure IRIS63: limited to exudative AMD
Product-specific effect on quality measures
No evidence found.
Product comparison
Approved and investigational therapies for GA named by the sponsor
Competition from approved products stated by the sponsor
Sponsor contrast with C3 and C5 inhibitors: target and functional outcome
Sponsor characterization of comparator photoreceptor analyses
Sponsor claim of vision preservation and the phase 2 primary endpoint result on which it rests
Independent systematic review: no peer-reviewed clinical results for C1q inhibition
“Although these therapies have progressed to clinical stages, no peer-reviewed publications reporting their clinical results are available to date. According to registry and sponsor-reported information, C1q blockade with ANX007 has progressed furthest among these candidates, advancing to Phase 3 trials following neuroprotective signals in Phase 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As these results are not yet supported by peer-reviewed publications, they were not included in the evidence synthesis and are reported here for context only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Head-to-head trial data against pegcetacoplan or avacincaptad pegol
No evidence found.
Place of product in therapy
Disease description
Definition and etiology
Definition: advanced non-neovascular AMD with well-demarcated atrophy of the RPE and choriocapillaris
Definition: confluent atrophy of photoreceptors, RPE, and choriocapillaris associated with scotoma
Bilateral and irreversible course of geographic atrophy
“Geographic atrophy (GA) is an advanced, vision-threatening form of age-related macular degeneration (AMD). This degenerative disease occurs with progressive loss of areas of the retinal pigment epithelium (RPE), photoreceptors, and underlying choriocapillaris.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Loss of visual function because of GA is considered irreversible and usually bilateral, with half of patients developing GA in both eyes within seven years of the initial GA diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Terminology: geographic atrophy as a subset of complete RPE and outer retinal atrophy
“Geographic atrophy (GA) is a well-established end-stage manifestation of age-related macular degeneration (AMD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, GA would be considered a subset of the more comprehensive term cRORA, with cRORA encompassing macular atrophy both with and without associated CNV.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The advanced non-exudative form of AMD - as described by clinico-pathological correlations and high-resolution in-vivo imaging modalities - is typically characterized by well-defined patches lacking photoreceptors, by degeneration or complete loss of retinal pigment epithelium (RPE) as well as by loss or attenuation of the choriocapillaris layer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multifactorial etiology: ageing, genetic susceptibility, and smoking
“AMD is a multifactorial disease related to aging, genetic susceptibility, and environmental risk factors such as cigarette smoking; it develops as a consequence of disruption of the normal homeostatic mechanisms of the retina.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Age-related macular degeneration is a multifactorial disorder, with dysregulation in the complement, lipid, angiogenic, inflammatory, and extracellular matrix pathways implicated in its pathogenesis. More than 50 genetic susceptibility loci have been identified, of which the most important are in the CFH and ARMS2 genes. The major non-genetic risk factors are smoking and low dietary intake of antioxidants (zinc and carotenoids).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: age, family history, ancestry, and smoking
Risk factors: smoking intensity and incident AMD in prospective cohorts
“Cigarette smoking is the most consistently reported environmental risk factor for AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a large prospective cohort study of 61 862 women over a 12-year follow-up period, 1 case of AMD developed per 1708 person-years among women who currently smoked 25 or more cigarettes per day compared with 1 case per 3740 person-years among those who had never smoked.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic risk: heritability and the CFH and ARMS2-HTRA1 loci
“Estimated heritability of late-stage AMD is approximately 71%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“indicating that approximately 71% of the risk of AMD is genetic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AMD genetics are unusual in that a small number of variants underlie a large proportion of heritability. The two loci with highest population attributable risk are CFH and ARMS2–HTRA1, and all other loci have low attributable risk, through low prevalence and/or weak association (with OR <1.2)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Evidence shows that ARMS2–HTRA1 risk variants increase the risk of GA development and its accelerated enlargement. However, the C3 risk variant is specifically associated with slower GA enlargement but the CFH risk variants are not associated with altered speed of GA enlargement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic risk: complement gene variants among late AMD susceptibility loci
“Early genome-wide and targeted sequencing studies identified a common variant in the CFH gene associated with AMD risk (CFH Y402H)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More recently, a meta-analysis and validation sequencing of GWAS data by the AMD Consortium, which evaluated >17,100 advanced AMD cases and >60,000 controls for common AMD risk variants, identified 19 single nucleotide polymorphisms (SNPs), of which four are contained within complement cascade genes (CFH, CFI, C3, C2/CFB).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Geographic atrophy secondary to age-related macular degeneration
Annual incidence of geographic atrophy in U.S. White adults aged 50 years and older
“Annual incidence (estimated from prevalence) of late AMD in American whites was 3.5 per 1000 aged ≥50 years (95% credible interval 2.5, 4.7 per 1000), equivalent to 293 000 new cases in American whites per year (95% credible interval 207 000, 400 000). Incidence rates approximately quadrupled per decade in age. Annual incidence GA rates were 1.9 per 1000 aged ≥50 years, NVAMD rates were 1.8 per 1000.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Number of new geographic atrophy cases per year in U.S. White adults
“This corresponds to approximately 293 000 new cases of late AMD each year (95% credible interval 207 000, 400 000), and 160 000 (95% credible interval 107 000, 234 000) and 148 000 (95% credible interval 103 000, 207 000) for GA and NVAMD, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Annual incidence of geographic atrophy by age group in U.S. White adults
“In those aged 65 years and older the annual incidence rate for late AMD is 7.8 per 1000 (95% credible interval 5.5, 10.6), 4.3 per 1000 for GA (95% credible interval 2.9, 6.2), and 3.9 per 1000 for NVAMD (95% credible interval 2.7, 5.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In those aged 80 years and older the annual incidence rates per 1000 are 19.4 (95% credible interval 13.8, 26.2), 10.9 (95% credible interval 7.2, 16.1), and 9.9 (95% credible interval 6.8, 14.0), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incident geographic atrophy in a high-risk clinical trial cohort over 5 years
“Of the remaining 6530 eyes at risk, 1099 (17.3%) eyes of 883 participants developed incident GA without prior neovascular disease during mean follow-up of 4.4 years. The Kaplan-Meier rate of incident GA was 19% of eyes at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fifteen-year incidence of pure geographic atrophy in an Australian population-based cohort
“By excluding 41 subjects with GA at baseline, of 2503 participants at risk of GA, incident pure GA (without coexisting neovascular AMD lesions) was confirmed in 57 participants, with a 15-year incidence of 3.6%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Annual incidence of late AMD in Europe (geographic atrophy and neovascular AMD combined)
“In the meta-analysis of incidence, the pooled annual incidence of any late AMD was 1.4 per 1 000 individuals (95% CI 0.8 to 2.6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Incident late AMD is estimated to increase from 400 000 per year today to 700 000 per year in 2050.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Geographic atrophy secondary to age-related macular degeneration
Annual prevalence of geographic atrophy in U.S. Medicare Advantage enrollees aged 65 years and older
“The total number of patients in the denominator was 2,175,803 (2018); 2,445,163 (2019); 2,680,322 (2020); and 2,905,366 (2021). The annual prevalence of GA was 0.56% (2018), 0.55% (2019), 0.48% (2020), and 0.51% (2021).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of GA was highest among individuals classified as White race (annual range 0.61% to 0.71%) and among patients with GA aged 75 years and older (range 0.95% to 1.11%). The proportion of patients with GA with co-occurring wet AMD was 25.6% to 28.0%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of geographic atrophy by age, race, and foveal involvement in U.S. Medicare Advantage claims
“The annual prevalence for GA without SFI was 0.21% to 0.25% across the assessment years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annual prevalence for GA with SFI was 0.27% to 0.31% during the same period. The annual prevalence of GA also was estimated at the level of eyes, with bilateral GA prevalence between 0.24% and 0.29% and unilateral GA between 0.23% and 0.27% from 2018 to 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the individuals classified as Black race, annual prevalence ranged from 0.09% to 0.11%. The annual prevalence of GA was calculated for 2 age categories; it was higher among individuals aged 75 years and older (0.95% to 1.11%) compared with people aged younger than 75 years (0.15% to 0.18%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of geographic atrophy in U.S. Medicare Advantage claims with a 24-month ascertainment window
“In the sensitivity analyses, including an additional 12 months for measuring prevalence, the annual prevalence of GA increased: 0.85% (2018), 0.83% (2019), 0.77% (2020), and 0.74% (2021)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lower prevalence of GA observed in claims data relative to other studies warrants careful consideration; coding practices likely will evolve with new GA therapies on the market.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estimated number of people in the United States with geographic atrophy
Late AMD in U.S. adults aged 40 years and older in 2019 (geographic atrophy and neovascular AMD combined)
“We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prevalence of late-stage AMD increased with age from 0.02% (95% UI, 0.01-0.05) among those 40 to 44 years (Figure 3) to 11.39% (95% UI, 6.45-18.46) among people 85 years or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“late-stage (defined as choroidal neovascularization and/or geographic atrophy in either eye)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Late AMD in U.S. adults aged 40 years and older in 2000 (geographic atrophy and neovascular AMD combined)
“The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global pooled prevalence of geographic atrophy by ancestry
“Eight (21%) of the 39 studies provided information on geographic atrophy and neovascular subtypes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analysis showed similar overall prevalence of geographic atrophy (0·44%, 95% CrI 0·15–1·36) and neovascular age-related macular degeneration (0·46%, 0·18–1·08).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Europeans had a higher prevalence of geographic atrophy (1·11%, 95% CrI 0·53–2·08) than Africans (0·14%, 0·04–0·45), Asians (0·21%, 0·04–0·87), and Hispanics (0·16%, 0·05–0·46).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of geographic atrophy and number affected in Nordic countries
“Prevalence of GA was estimated to 0.4% (95% confidence intervals [CI]: 0.2%-0.8%), 1.5% (95% CI: 0.7%-2.6%), and 7.6% (95% CI: 4.6%-11.3%) for individuals aged 60-69, 70-79, and 80+ years, respectively. In Nordic countries, we estimate a total of 166 307 individuals with GA in 2023, increasing to 277 893 in 2050.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of geographic atrophy in Asian populations
“The pooled overall prevalence of GA was 1.57 per 1000 persons (95% confidence interval [CI], 1.04-2.10), which was 3 times less than that of neovascular AMD of 5.20 per 1000 persons (95% CI, 3.97-6.43). Compared with those aged 50 to 59 years, the prevalence of GA increased from 0.34 per 1000 persons (95% CI, 0.07-0.62) to 2.90 per 1000 persons (95% CI, 1.55-4.25) in those aged ≥70 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Late AMD in Europe, 2013 to 2040 (geographic atrophy and neovascular AMD combined)
“Prevalence of early AMD increased from 3.5% (95% confidence interval [CI] 2.1%–5.0%) in those aged 55–59 years to 17.6% (95% CI 13.6%–21.5%) in those aged ≥85 years; for late AMD these figures were 0.1% (95% CI 0.04%–0.3%) and 9.8% (95% CI 6.3%–13.3%), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This model also displayed that the number of people with late AMD in Europe will increase from 2.7 million in 2013 to 3.9 million by 2040 (Fig 8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Late AMD in Europe among adults aged 60 years and older (geographic atrophy and neovascular AMD combined)
Natural history, survival, and mortality
Lesion growth: pooled rate across natural history studies
“The pooled mean GA growth rate was 1.66 mm2/year (SD = 1.27 mm2/year, I2 = 97.0%, p < 0.001) from 23 studies (3,078 patients) reported with growth rate in mm2/year and 0.33 mm/year (SD = 0.17 mm/year, I2 = 83.0%, p < 0.001) from 12 studies (1,808 patients) reported with growth rate in mm/year. Larger mean baseline GA area in mm2 was associated with larger mean growth rate in both mm2/year and mm/year (p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lesion growth: constant radial enlargement in untreated eyes
“We included 25 studies with data from 2942 eyes. The RLM yielded the best goodness of fit and predictive performance of GA progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The GA radius enlarged at a constant rate of 0.163 mm/year (95% confidence interval, 0.158-0.167 mm/year), which was independent of time (r = -0.108). The RLM predicted the mean age of onset of GA as 67.4±5.2 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lesion growth: AREDS2 cohort
“In the prevalence cohort, the change over time in square root of GA area was 0.29 mm/year (95% CI 0.27–0.30), i.e. 0.17 disc diameters/year, or (without square root transformation) 1.42 mm2/year (1.33–1.52), i.e. 0.61 disc areas/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GA enlargement was significantly faster for non-central than for central GA at 0.31 mm/year (0.30–0.33) and 0.22 mm/year (0.20–0.24), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lesion growth: AREDS cohort
“Median initial lesion size was 4.3 mm2. Average change in digital area of GA from baseline was 2.03 mm2 (standard error of the mean, 0.24 mm2) at 1 year, 3.78 mm2 (0.24 mm2) at 2 years, 5.93 mm2 (0.34 mm2) at 3 years, and 1.78 mm2 (0.086 mm2) per year overall.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lesion growth: prospective single-center natural history study
“The median overall enlargement rate was 2.1 mm2/year (mean, 2.6 mm2/year). Eyes with larger areas of atrophy at baseline tended to have larger enlargement rates, but knowledge of prior rates of enlargement was the most significant factor in predicting subsequent enlargement rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lesion growth and visual acuity loss over 24 months in the Proxima A and B studies
“At 24 months, adjusted mean (standard error) change in GA lesion area from baseline was 3.87 (0.15) mm2 in participants with bilateral GA (Proxima A), 3.55 (0.16) mm2 in the fellow eye CNV cohort (Proxima B), and 2.96 (0.25) mm2 in the fellow eye intermediate AMD cohort (Proxima B).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjusted mean (standard error) changes in BCVA and LLVA (ETDRS letters) in the study eye from baseline to 24 months were -13.88 (1.40) and -7.64 (1.20) in Proxima A, -9.49 (1.29) and -7.57 (1.26) in Proxima B fellow eye CNV cohort, and -11.48 (3.39) and -8.37 (3.02) in Proxima B fellow eye intermediate AMD cohort, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Foveal progression: time from noncentral to central geographic atrophy in AREDS
“Median time to developing central GA after any GA diagnosis was 2.5 years (95% confidence interval, 2.0-3.0). Average visual acuity decreased by 3.7 letters at first documentation of central GA, and by 22 letters at year 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Foveal progression: 2-year and 4-year rates in AREDS2
“For the 628 participants (and 734 eyes) whose incident GA was non-central GA at its first appearance, mean follow-up time was 4.7 years (SD 0.8; IQR 0.7). The Kaplan-Meier plot for the progression from non-central to central GA in these eyes is shown in Figure 5, with a 32% 2-year rate and a 57% 4-year rate of progression to central GA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Foveal progression: 5-year change in a U.S. population-based cohort
“Of 53 eyes with multiple visits, the overall increase in atrophy was 6.4 mm2 over a 5-year period. The atrophy progressed to involve the foveal center in 47% of eyes and there was a mean decrease of 17 letters read correctly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Foveal progression and visual acuity change over 24 months in the IRIS Registry
“In total, 69 441 patients were included: 44 120 (64%) GA:GA and 25 321 (36%) GA:nAMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both GA:GA and GA:nAMD cohorts, nonsubfoveal study eyes had better mean (standard deviation) VA at index (67 [19.3] and 66 [20.3] letters) than subfoveal eyes (59 [23.9] and 47 [26.9] letters), and 24-month mean VA changes were similar for nonsubfoveal (−7.6 and −6.2) and subfoveal (−7.9 and −6.5) subgroups. Progression to subfoveal GA occurred in 16.7% of nonsubfoveal study eyes in the GA:GA cohort and 12.5% in the GA:nAMD cohort. More new-onset study-eye nAMD was observed in the GA:nAMD (21.6%) versus GA:GA (8.2%) cohorts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Foveal progression in U.S. Medicare Advantage claims
“At index, 4,781 (50.3%) individuals had GA without SFI and 4,697 (49.4%) had GA with SFI. Among individuals with GA without SFI at index, 479 (10.2%) progressed to GA with SFI during the 12-month follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Significant predictors of progression to GA with SFI were wet AMD at baseline (HR [CI] = 5.70 [4.63-6.99], P < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity loss over 4 years by baseline acuity and lesion proximity to the fovea
“We included 1351 eyes from 994 participants, including 594 eyes from 464 participants with 4-year BCVA follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, 483 eyes that met both criteria of baseline BCVA ≥ 40 letters and GA lesions involving or within 1 mm of the foveal center showed significant BCVA loss over 4 years (mean change = −11.33 letters [95% confidence interval = −12.80 to −9.84]), with faster GA progression associated with larger BCVA loss (P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity loss over 2 years in the lampalizumab trials
Visual acuity loss and progression to neovascular AMD in bilateral geographic atrophy in U.K. practice
“In the worse-seeing eye, 40.1% lost ≥10 letters in 2.4 years. Among patients with baseline and 24-month VA measurements, mean VA decline was 6.1 letters in the worse-seeing eye (n = 413) and 12.4 letters in the better-seeing eye (n = 414). The rate of progression to CNV in either eye was 7.4% per patient-year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression to neovascular AMD after incident geographic atrophy in AREDS2
Progression from unilateral to bilateral geographic atrophy
Mortality: total area of geographic atrophy and all-cause mortality
“During a median follow-up of 6.8 years, 48 (23.0%) participants with GA died. In adjusted models, accounting for age, sex, and health status, participants with total GA area in the highest quartile had a significantly increased risk of all-cause mortality compared to those with total GA area in the lowest quartile (hazard ratio [HR], 3.42; 95% confidence interval [CI], 1.32-8.86; P = 0.011). GA effective radius growth rate, bilateral disease, and the presence of foveal center involvement were not significantly associated with mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: late AMD and all-cause and cardiovascular mortality (geographic atrophy and neovascular AMD combined)
“Late AMD was associated with elevated rates of all-cause (nine studies, hazard ratio (HR) 1.20, 95% confidence interval, CI, 1.02-1.41) and cardiovascular mortality (six studies, HR 1.46, 95% CI 1.13-1.98), but early AMD was not (all-cause mortality, 10 studies, HR 1.06, 95% CI 0.98-1.14; cardiovascular mortality, five studies, HR 1.12, 95% CI 0.96-1.31).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of all-cause mortality and cardiovascular mortality associated with early AMD were 1.08 (1.00-1.18) and 1.05 (0.89-1.24), and the associations with late AMD were 1.23 (1.11-1.36) and 1.28 (1.04-1.57), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Disease mechanism: stressors of the RPE, drusen, and complement-mediated inflammation
“The pathogenesis of GA is multifactorial and is generally thought to be triggered by intrinsic and extrinsic stressors of the poorly regenerative RPE, particularly oxidative stress caused by the high metabolic demand of photoreceptors, photo-oxidation, and environmental stressors such as cigarette smoke.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Components of drusen (cellular debris, lipids, lipoproteins, amyloid deposits) and lipofuscin (by-products of photoreceptor outer-segment degradation, A2E), as well as other products of oxidative stress such as advanced glycation end products, are thought to trigger inflammation via multiple pathways, such as the complement cascade and the NLRP3 inflammasome. When the regulatory components in these pathways are compromised, as is the case with several GA-linked genetic risk factors in the complement cascade, this inflammation can ultimately lead to the retinal cell death characteristic of GA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The underlying pathophysiology of GA is complex and thought to involve chronic inflammation due to overactivation of the complement system that leads to the loss of photoreceptors, retinal pigment epithelium (RPE), and the underlying choriocapillaris.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ageing changes and extracellular deposits in the outer retina
“Aging-related changes cause increasing resistance of blood vessels and reduction of choriocapillaris density, lipid and lipoprotein deposition in the Bruch membrane, and reduction in photoreceptor density.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Extracellular deposits, collectively known as drusen, comprise materials such as lipids, minerals, and proteins and are implicated in the development and progression of AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement system: three lines of evidence in geographic atrophy
“The case for complement cascade dysfunction in AMD is supported by three key lines of evidence. Landmark genome-wide association studies (GWAS) identified AMD-associated variants in complement factor genes, particularly those such as CFH that promote alternative complement pathway termination on host cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, patients with GA exhibit alterations in complement cascade components both systemically and locally within the eye. Finally, these observations are supported by preclinical research in vitro and in mice, which have demonstrated that complement dysfunction is associated with GA-like pathology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analyses of donor eye tissue demonstrated the presence of complement proteins such as C3 and C5 in drusen of patients with AMD. In addition, post-mortem studies have shown that C5b-9 (membrane attack complex) accumulates in the choriocapillaris and BrM with increasing age and in eyes with AMD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Indeed, a large number of high-risk genetic variants are found in genes encoding complement system regulatory proteins (for example, CFH, CFI, C3 and FB/C2)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement regulation: CFH binding to C3b and the alternative pathway
“Each of the CFH Y402H, CFH R1210C, and C3 K155Q variants are predicted to reduce the interaction between CFH and C3b, thus diminishing complement cascade inactivation and potentially increasing feedback amplification of the alternative complement pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement pathways: classical pathway initiation by C1 and convergence at C3 and C5
“The classical complement pathway is activated when the C1 complex binds specific antigen–antibody complexes, often immunoglobulin M (IgM), IgG3, or IgG1. This induces a conformational change in the C1 complex, allowing it to cleave C4 and C2 to generate the C4bC2b complex. C4bC2b acts as the C3 convertase of the classical pathway, cleaving C3 into C3a and C3b.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The oldest evolutionary signaling pathway of the three, the alternative complement pathway acts both independently of, and as an amplification loop for, the classical and lectin pathways.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The classical, lectin, and alternative complement pathways converge with the cleavage of C3 into C3a and C3b and the subsequent formation of the C5 convertase complexes of C4bC2bC3b (classical, lectin pathways) or C3bC3bBb (alternative complement pathway). These C5 convertase complexes cleave C5 into C5a and C5b, initiating the final steps of the complement cascade.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Classical pathway and C1q in geographic atrophy: sponsor-authored review
“However, the involvement of the different complement pathways (classical, lectin, alternative), and thus the optimal complement inhibition target, has yet to be fully defined. There is evidence that C1q, the initiating molecule of the classical pathway, is a key driver of complement activity in AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Multiple lines of evidence suggest that the classical pathway may be a key initiator of complement activation in GA. First, C1q is present in all layers of the outer retina in GA along with numerous C1q-activating ligands that accumulate throughout disease initiation and progression. Second, C1q and the classical pathway are implicated by retinal pathology in GA and in animal models of GA. Third, in RPE culture models, C1q triggers C5b-9 deposition on basement membrane components and contributes to induction of the inflammasome and cell necrosis. Fourth, inhibition of C1q and downstream C4 is protective in animal models of photoreceptor cell loss. Fifth, C1q accumulates on photoreceptor cell synapses in mice with age and light-induced injury, consistent with the unique role it plays in synapse elimination and neurodegeneration in other disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C1q is highly expressed in infiltrating macrophages within all layers of the outer retina (OPL, POS, RPE, and choroid layers) in GA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
C1q and photoreceptor synapse elimination: sponsor-authored review
“Photoreceptor cell stress in GA caused by decline in RPE function and other factors may lead to a process of synapse elimination, neuroinflammation and neuronal loss that is common in multiple neurodegenerative disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In GA, with declining RPE function and neuronal stress, C1q on synapses may activate the classical pathway, and as in other neurodegenerative disorders, result in compromised synapse function and microglial cell recruitment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While blocking downstream components of all three pathways has provided promise in clinical studies, targeting the classical pathway in GA would provide a more selective approach with the potential for increased efficacy and safety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical evidence: subretinal macrophage C1q in photo-oxidative retinal degeneration
“Wild-type (WT), C1qa knockout (C1qa−/−) and mice treated with a C1q inhibitor (ANX-M1; Annexon Biosciences), were exposed to photo-oxidative damage (PD) and were observed for progressive lesion development.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Retinal neutralisation of C1q, using an intravitreally-delivered anti-C1q antibody, reduced the progression of retinal degeneration following PD, while systemic delivery had no effect. Finally, retinal C1q was found to be expressed by subretinal microglia/macrophages located in the outer retina of early AMD donor eyes, and in mouse PD retinas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our data implicate subretinal macrophages, C1q and the classical pathway in progressive retinal degeneration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
RPE dysfunction preceding photoreceptor cell death
“Ultimately, the interplay of the above-described pathological changes including chronic tissue hypoxia owing to choriocapillaris microvasculopathy, chronic inflammation and ROS-mediated oxidative stress may lead to the actual ‘end-stage’ of AMD, which is neurodegeneration, specifically photoreceptor cell death causing irreversible vision loss. In ageing and AMD, rods degenerate ahead of cones” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Photoreceptor cell death is presumably directly induced by the breakdown of multiple systems that are crucial for photoreceptor outer segment morphogenesis, phototransduction and metabolic homeostasis. These systems are mainly maintained by the RPE, which, in the course of AMD undergoes degeneration, finally leading to cell death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanisms of lesion enlargement distinct from disease onset
“These findings suggest that biological mechanisms involved in GA enlargement differ at least partially from those underlying its nascence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, in patients with established GA, targeting complement might not be efficacious as other factors and mechanisms have been hypothesized to drive GA enlargement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Guideline initial evaluation: history elements
| Element of the initial history | Quoted text |
|---|---|
| Symptom: distortion | “Metamorphopsia” |
| Symptom: reduced acuity | “Decreased vision” |
| Symptom: central field loss | “Scotoma” |
| Symptom: low-luminance function | “Difficulties in dark adaptation” |
| Family history | “Family history, especially family history of AMD” |
| Social history | “Social history, especially a quantitative smoking history” |
Guideline imaging: optical coherence tomography and OCT-based atrophy classification
Guideline position on genetic testing
Fundus autofluorescence: decreased signal over atrophy and regulatory acceptance as a trial endpoint
“FAF imaging provides high-contrast retinal images that are particularly valuable for the diagnosis and evaluation of GA as loss of RPE and fluorophores in atrophic areas is associated with a decreased FAF signal” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, the FAF signal using blue light excitation is physiologically reduced in the central macula mainly due to signal absorbance by the macula pigments lutein and zeaxanthin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Atrophy in these areas may therefore not be visible by blue light excitation FAF imaging. Hence, simultaneous OCT or NIR imaging is recommended, particularly in patients with suspected foveal involvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fundus autofluorescence imaging is particularly useful for identifying and monitoring geographic atrophy progression, and regulatory authorities have accepted its application in clinical trials to assess the change in geographic atrophy lesion area as the primary outcome measure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consensus OCT definition of complete RPE and outer retinal atrophy
“OCT was proposed as the reference standard or base imaging method to diagnose and stage atrophy. Other methods, including fundus autofluorescence, near-infrared reflectance, and color imaging, provided complementary and confirmatory information.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Specific OCT criteria to diagnose cRORA were proposed: (1) a region of hypertransmission of at least 250 μm in diameter, (2) a zone of attenuation or disruption of the RPE of at least 250 μm in diameter, (3) evidence of overlying photoreceptor degeneration, and (4) absence of scrolled RPE or other signs of an RPE tear.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Features of photoreceptor degeneration include all of the following: loss of the interdigitation zone, ellipsoid zone, and external limiting membrane and thinning of the outer nuclear layer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consensus OCT definition of incomplete RPE and outer retinal atrophy
“In the context of drusen, iRORA is defined on OCT as (1) a region of signal hypertransmission into the choroid and (2) a corresponding zone of attenuation or disruption of the RPE, and (3) evidence of overlying photoreceptor degeneration. The term iRORA should not be used when there is an RPE tear. Longitudinal studies confirmed the concept of progression from iRORA to cRORA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consensus update: en face OCT for measuring complete RPE and outer retinal atrophy
“The CAM group affirmed the role of en face OCT as a critical adjunct to traditional B-scan analysis, for more precise measurement of the area of cRORA lesions and for distinguishing threshold cRORA from smaller incomplete retinal pigment epithelial and outer retinal atrophy lesions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The consensus panel’s adoption of the abnormal RPE band term as a unified category for RPE abnormalities may reduce confusion regarding the definition of RPE degeneration and has the potential to improve interreader variability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expert panel recommendations: OCT as the preferred method and the role of fundus autofluorescence
“Panelists agreed that OCT was the preferred imaging method to identify GA because of both its ease of use and accessibility among optometrists and ophthalmologists.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As disease progresses, OCT remains the primary imaging modality for GA identification because of the prominent, readily identifiable hypertransmission that occurs beyond atrophic lesions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fundus autofluorescence does not confer much additional information compared to what can be obtained from OCT (B-scan and en face). Additionally, patient tolerance to FAF imaging is lower because of the high light intensity used during acquisition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On FAF, GA lesions appear as areas of decreased autofluorescence (hypoautofluorescence) due to a lack of lipofuscin as a result of RPE cell atrophy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expert panel recommendations: screening examinations and referral
“Among all ECPs, regardless of practice specialty, there was unanimous agreement that there is currently no standardized process by which GA is identified and diagnosed, thus revealing a significant unmet need.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary ECP should inquire with the patient about GA symptoms, perform a comprehensive ocular examination that includes best-corrected visual acuity assessment, and conduct a retinal examination and OCT scan to identify any signs of AMD in one or both eyes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A nonurgent referral to a retina specialist is recommended for any suspected GA in one or both eyes, whereas a more urgent referral should be made for any patient with suspected neovascular AMD (nAMD)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delphi consensus on diagnostic imaging
“Consensus was achieved in several topics related to diagnostic imaging, including the use of optical coherence tomography, and the urgent need for treatments and beneficial interventions to reduce the associated burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Imaging modalities for detection and limits of visual acuity as a marker
“Because best-corrected VA does not correlate well with GA lesions or progression, alternative clinical endpoints are being sought.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Detection of GA can be achieved with a number of different imaging techniques, including color fundus photography, fluorescein angiography, fundus autofluorescence (FAF), near-infrared reflectance, and spectral-domain optical coherence tomography.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Central vision: scotoma and progressive central visual field loss
“Although GA can result in significant visual function deficits in reading, night vision, and dark adaptation, and produce dense, irreversible scotomas in the visual field, the initial decline in VA may be relatively minor if the fovea is spared.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Areas of GA enlarge over time, leading to progressive central visual field loss” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Central visual loss is typically related to late AMD stages associated with photoreceptor loss. When the areas of photoreceptor loss expand, patients often lose central vision, markedly decreasing the ability to read or recognize faces.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central vision: symptom onset and course compared with neovascular AMD
Visual acuity: preserved acuity with foveal sparing and loss with central involvement
Reading: reduced maximum reading rate in eyes with good visual acuity
“Half the eyes with GA, but none of the drusen eyes, had maximum reading rates below 100 words per minute.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The eyes with GA with good VA have profound decreases in visual function, particularly in dim lighting and in reading.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Reading: difficulty with reading as the main patient complaint
“The main complaint among patients was difficulties regarding daily tasks, especially reading and other near activities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All participants had issues with reading since the onset of GA. Many participants had reluctantly given up reading for pleasure, mainly because it took a lot longer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When it came to reading for necessity, participants had difficulties with reading menus, reading sell-by dates, prices and other information on products, and using card machines in shops.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Low-luminance vision: worse function in dim light and its predictive value
“These endpoints are of particular interest because patients with AMD, especially those with GA, often experience worse functional difficulties in dimly lit environments than in bright conditions” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The baseline low-luminance deficit (LLD) in VA was a strong predictor of subsequent VA loss for all levels of baseline VA. Within the good baseline VA group, the relative risk (RR) of 3-line loss for the worse LLD group compared with the better LLD group was 2.88 (95% confidence interval [CI], 1.13-7.35).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dark adaptation: delayed recovery after exposure to bright light
“In the early stages of AMD, patients commonly experience alterations in visual function characterized by a delay in dark adaptation; diminished sensitivity to contrasts; and, subsequently, the appearance of scotomas in their central visual field. As the area of atrophy increases to involve larger areas of the central retina, patients begin to experience a more pronounced deterioration in central visual acuity, slower reading speed, distorted vision, challenges in discerning colors, extremely slow recovery in dark adaptation following exposure to bright light, and substantial impairment of overall visual function” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Face recognition: difficulty recognizing faces with central field loss
“Participants in both groups were affected by a range of symptoms from GA with most experiencing varying levels of disrupted peripheral and central vision; intolerance to brightness and glare; dizziness and problems with face recognition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GA is known to cause significant functional and psychosocial burden, where patients with subfoveal GA struggle with facial recognition, driving and navigation, and parafoveal GA causing significant issues with reading and complex visual scenes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Light sensitivity and other patient-reported symptoms: concept elicitation interviews
“In total, 25 symptoms and 36 impacts were reported by 19 patients with GA, with seven symptoms and 11 impacts identified as salient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The symptoms with the highest average disturbance rating were night blindness, general fatigue, dry eyes, and sleep disturbance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The impacts with the highest average disturbance rating were fear, difficulty driving, and difficulty reading.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these VISSA-10 items, blurry vision, poor light adaptation, defective color vision, and sensitivity to brighter light have been reported by patients with GA in previous studies, but the saliency of these symptoms was not measured” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Driving: visual acuity below the driving standard at diagnosis of bilateral GA
Perceptual symptoms: Charles Bonnet syndrome visual hallucinations
“The prevalence of CBS was 25 in 120 (20.8%). Thirteen (52%) of those with CBS were not previously informed of the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One in five with GA has CBS, which ranks GA as an eye disease with one of the highest reported prevalences of CBS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical signs: well-demarcated atrophy with visible choroidal vessels
Long-term morbidity
Legal blindness: share of U.S. legal blindness attributed to geographic atrophy
“Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and is responsible for approximately 20% of legal blindness in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Legal blindness: progression to blindness in U.S. Medicare Advantage claims
“Among individuals with GA without SFI at index, 173 (3.6%) developed irreversible blindness, compared to 312 (6.6%) of those with SFI, and 51 (0.5%) individuals without GA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both diagnosis of GA without SFI (hazard ratio [HR] [CI] = 6.77 [4.98-9.35], P < 0.001) and diagnosis of GA with SFI (HR [CI] = 12.59 [9.43-17.16], P < 0.001) were strongly associated with increased risk of developing irreversible blindness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Irreversible blindness was defined as any patient with a diagnosis code for blindness (ICD-10-CM = H54.0, H54.1, H54.4, H54.8) in the claims database.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Legal blindness and loss of driving eligibility in bilateral geographic atrophy in U.K. practice
“Progression to blindness (visual acuity [VA] <20 letters or Snellen 3/60 in the better-seeing eye), driving ineligibility (VA ≤70 letters or Snellen 6/12 in the better-seeing eye)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At first record of GA, 7.1% had a VA in the better-seeing eye equal to or lower than the cutoff for blindness registration and 71.1% had a VA that would have rendered them ineligible to drive. Over time, 16% became legally blind (median time to outcome, 6.2 years) and 66.7% became ineligible to drive (median time to outcome, 1.6 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Loss of driving-level acuity and progression to 20/200 or worse over 24 months in the IRIS Registry
“Among study eyes with VA of 20/40 or better at baseline, the rates of decline were similar in both cohorts, with 30.2% in the GA:GA cohort and 30.0% in the GA:nAMD cohort progressing to VA worse than 20/40 at 24 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among study eyes with VA worse than 20/40 and better than 20/200 at index, 29.7% of the GA:GA and 27.6% of the GA:nAMD cohorts progressed to VA 20/200 or worse at 24 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual impairment in eyes with geographic atrophy in European population-based studies
“Before 2006, 54.2% of eyes with GA were visually impaired, and 79.8% of eyes suffering from CNV were visually impaired. From 2006 onward, the proportion of visually impaired eyes remained the same for GA (47.6%; P = 0.40), but dropped to 66.2% (P = 0.026) for CNV (Fig 7A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blindness and vision impairment due to AMD worldwide, 1990 to 2021 (all AMD subtypes combined)
“Cases of moderate vision loss rose from 2·13 million (95% UI 1·64–2·76) in 1990 to 5·39 million (4·18–7·00) in 2021, severe vision loss increased from 0·39 million (0·28–0·51) to 0·79 million (0·58–1·03), and blindness rose from 1·12 million (0·84–1·47) to 1·88 million (1·41–2·46).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Falls and fractures in U.S. claims databases
“Risks of falls (RR 1.16–1.36) and fractures (RR 1.17–1.29) in the 4 years following the index date were higher in patients with GA compared with controls. Patients with bilateral GA and subfoveal involvement had the most pronounced increase in risk of falls (RR 1.42–1.49) and fractures (RR 1.33–1.45).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Injurious falls in U.S. Medicare Advantage claims by geographic atrophy and blindness status
“Although the overall rate of all-cause injurious falls per 100 person-years did not differ meaningfully between patients with GA only and those with no GA (P=0.122), patients with GA only had 1.24 (95% CI: 1.05, 1.45) times more all-cause falls with head injuries and 0.67 (95% CI: 0.51, 0.89) times fewer all-cause falls with joint dislocations per 100 person-years compared to patients with no GA (both P<0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with GA + B had higher rates of both all-cause and ophthalmic condition-related injurious falls, with 1.69 (95% CI: 1.29, 2.23) times more all-cause injurious falls per 100 person-years and 5.94 (95% CI: 3.40, 10.36) times more ophthalmic condition-related injurious falls per 100 person-years than patients with GA only (both P<0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fall-related injuries in a matched U.S. Medicare Advantage cohort
Depression: new-onset depression in a matched U.S. Medicare Advantage cohort
“In this study, the prevalence of depression at baseline was observed in one-fifth or more of the study sample (ranged 19.9%-22.6%). Furthermore, the incidence of new onset depression during the follow-up period was greater in GA cohort than non-GA cohort (86.6 vs 77.3 per 1,000 person years, P = 0.004).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Institutionalization: nursing home or assisted living admissions in U.S. claims databases
“Compared to controls, patients with GA also had an increased risk for hospitalization (RR 1.18–1.27), emergency department visits (RR 1.18–1.21), nursing home or assisted living admissions (RR 1.06–1.28), and outpatient visits (RR 1.05–1.08).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, the risk of ED visits was 18% to 21% (RR [95% CI] 1.18 [1.11–1.25] to 1.21 [1.18–1.23]) higher (Fig. S2 in the Supplementary Material), and the risk of nursing home or assisted living facility admissions was 6% to 28% (RR [95% CI] 1.06 [0.99–1.13] to 1.28 [1.24–1.31]) higher” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Geographic atrophy secondary to age-related macular degeneration
Humanistic burden and health-related quality of life
Vision-related quality of life compared with age-matched peers: NEI VFQ-25
“Vision-related functioning and QoL were poorer in patients with vs without GA (n=137 vs 52), as demonstrated by significantly lower NEI-VFQ-25 composite score (mean, 53.1 vs 84.5 points, respectively; P<0.001), as well as lower subscale scores for near activities, distance activities, dependency, driving, social functioning, mental health, role difficulties, color vision, and peripheral vision.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lower QoL observed in the GA group remained after adjusting the NEI-VFQ-25 composite score for age and sex (adjusted difference between groups, −28.82; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within this study conducted in the United Kingdom, Germany, Ireland, and Canada, patients with physician-confirmed diagnosis of GA secondary to AMD were recruited and interviewed prospectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Driving, legal blindness registration, and loss of independence
“Eighteen percent of patients with GA were either registered as legally blind according to legislation in the relevant country, or were going through the assessment process for registration (Table 3). Over half of patients with GA had a driving license (55.5%). However, half (52.0%) of these patients did not feel confident driving during the day and most (88.0%) did not feel confident driving at night.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the NEI-VFQ-25 questionnaire, fewer patients in the GA group were currently driving than those in the non-GA group (27.6% vs 69.2%, respectively), and among the patients who did not drive, 73.9% had given up driving in the GA group compared with only 25.0% in the non-GA group. Eyesight was reported as the most common reason for giving up driving in the GA group (80.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual function and lesion determinants of NEI VFQ-25 scores
“The VRQoL composite score was impaired: 69.96 (24.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the multivariable cross-sectional analysis, predictors of the VRQoL composite score were BCVA, GA size, and low-luminance visual acuity (LLVA) for the better eye and BCVA, foveal sparing status, and LLVA for the worse eye (cross-validated R2 = 0.32).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most significant associations with VRQoL scores for distance and near activities were observed in the inner lower and inner left subfields of the BE, respectively. For patients with foveal-sparing GA, the LLVA of the BE stood out as the most influential variable across all VRQoL scales.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Change in vision-related quality of life after development of geographic atrophy
“Among AREDS participants with NEI VFQ-25 data available, 358 eyes (298 participants) developed any GA. None of the quality of life measures differed significantly pre- and post-CGA. Rasch-calibrated subscale score for visual function and composite scores declined more quickly after NCGA (difference in slope [post minus pre]: –0.10 logit/yr [95% confidence interval: –0.18, –0.01], P = 0.03; –0.78 points/yr [95% confidence interval: –1.47, –0.08], P = 0.03, respectively) and after any GA (–0.09 logit/yr [95% confidence interval: –0.16, –0.01], P = 0.02; –0.68 points/yr [95% confidence interval: –1.29, –0.07], P = 0.03, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A clinically meaningful decrease in VRQOL was defined as a loss of 5 points, and the median time to significant loss of VRQOL was 4.2 years (95% CI, 3.0–5.7 years) in 259 patients,24 corresponding to a decline in 1.68 ± 4.65 NEI VFQ-25 units/year (107 patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual function decline over 48 weeks in the sham-controlled Chroma and Spectri trials
“Functional end points included change in BCVA from baseline to week 48, low-luminance visual acuity, mesopic microperimetry (number of absolute scotomatous points, mean macular sensitivity), binocular and monocular maximum reading speed, and 2 validated patient-reported outcome measures: Functional Reading Independence Index and 25-item National Eye Institute Visual Function Questionnaire.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Enlargement of GA area, approximately 2 mm2/year on average across all treatment groups in each study, was accompanied by overall deterioration in all functional end points.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with bilateral GA experienced a consistent decline in visual function over 48 weeks, but measures of visual function were not correlated strongly with GA lesion area.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Functional reading independence
“Qualitative interviews (n = 40) yielded a 10-item FRI Index, which was refined to seven items in quantitative testing (n = 100). Strong internal consistency (marginal reliability = 0.90) and reproducibility (intraclass correlation coefficient = 0.86) were shown.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Convergent validity with binocular measures was strong (Spearman's correlation = 0.72 for reading speed, 0.66 for NEI-VFQ-25).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The FRI Index demonstrated good reliability and validity in patients with GA. Further study in a broader GA population is warranted to confirm responsiveness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Daily activities affected: ethnographic and focus group studies
“Sivaprasad et al25 investigated the impact of GA on daily routine activities of 16 patients with GA in Germany, the United Kingdom (UK), and the US. Patients reported difficulties with reading (100%), driving (75%), and watching television, films, or theatre (68.8%). Other concepts reported included loss of independence (56.3%) and difficulty in recognizing faces (62.5%) or performing household activities (62.5%).25” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Activities of daily living and NEI VFQ-39 scores: United States patient survey
“Nearly 86% of patients (n = 88) stated that they did not currently drive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) driving subscale score of the NEI VFQ-39, 9.7 (20.4), was the lowest score compared with the other subscales, indicating a negative impact of GA on driving.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moderate to extreme difficulty reading a newspaper and small print (eg, medicine bottle, legal forms) was reported by 67% and 68% of patients, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Losing their independence was the biggest concern reported by 56% of patients; 51% of patients worried about their eyesight most or all the time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) vision-specific mental health subscale score, related to the items described previously, was 46.4 (25.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Depression and anxiety: Medicare Advantage claims
“In this study, the prevalence of depression at baseline was observed in one-fifth or more of the study sample (ranged 19.9%-22.6%). Furthermore, the incidence of new onset depression during the follow-up period was greater in GA cohort than non-GA cohort (86.6 vs 77.3 per 1,000 person years, P = 0.004).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, approximately 20% of patients with GA in the current study had evidence of an anxiety disorder during the follow-up period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Depression and visual performance in age-related macular degeneration
“Results showed that 17 patients (33%) were depressed at baseline and had worse acuity (P = 0.04) and greater levels of vision-specific (P = 0.03) and general (P = 0.002) physical disability than nondepressed patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An increase in depressive symptoms over time predicted a decline in self-reported visual function independent of changes in visual acuity or medical status (P < 0.05).33” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health utility: EQ-5D index in participants with geographic atrophy
| Acceptability of injections | Participants, No. | EQ-5D health index score, median (IQR) |
|---|---|---|
| Unacceptable | “27”View highlighted excerpt for this quote | “0.75 (0.65 to 0.88)”View highlighted excerpt for this quote |
| Acceptable | “126”View highlighted excerpt for this quote | “0.74 (0.60 to 0.84)”View highlighted excerpt for this quote |
Health utility values by visual acuity in the better-seeing eye: age-related macular degeneration overall
“The mean utility value for the total group with age-related macular degeneration was 0.72 (95% confidence interval [CI], 0.66-0.78) using the time trade-off method and 0.81 (95% CI, 0.76-0.86) using the standard gamble method.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Using the time trade-off method correlated with the visual acuity in the better-seeing eye, the results were as follow: group 1, 0.89 (95% CI, 0.82-0.96), group 2, 0.81 (95% CI, 0.73-0.89), group 3, 0.57 (95% CI, 0.47-0.67), group 4, 0.52 (95% CI, 0.38-0.66), and group 5, 0.40 (95% CI, 0.29-0.50).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported importance of functional benefit from treatment
“Among the 153 participants, 81 (53%; 95% CI, 45-61) reported IVCIs were very much or extremely acceptable under the theoretical scenarios provided. The proportion finding IVCIs acceptable rose to 82% (95% CI, 76-88) when including those who rated prospective treatment as moderately acceptable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While current treatments do not result in vision outcome benefits, perceived effectiveness by patients was associated with acceptability, emphasizing the desire to quantify vision functional benefit concomitant with anatomical slowing of progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Incremental all-cause healthcare costs: United States Medicare Advantage claims
“Patients with GA only incurred higher annual all-cause total healthcare costs compared to patients with no GA ($26,696 vs $25,524), spending an average of $1,171 (95% CI: 204, 2,138) more per year (P=0.018). The difference in all-cause total healthcare costs was primarily driven by higher annual OP visit costs ($10,706 vs $9,996; adjusted cost difference: $740; 95% CI: 194, 1,286; P=0.008).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to patients with GA only, patients with GA + VI incurred higher all-cause total healthcare costs ($35,654 vs $30,558), spending an average of $5,096 (95% CI: 2,811, 7,381) more per year (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With the additional burden of blindness, patients with GA + B spent an average of $9,952 (95% CI: 6,172, 13,733) more per year in all-cause total healthcare costs compared to patients with GA only (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs were inflation-adjusted to 2021 US dollars using the medical care component of the Consumer Price Index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare resource utilization rate ratios: United States Medicare Advantage claims
“The study included 18,119 patients with GA only, 2,285 with GA + VI, 1,716 with GA + B, and 72,476 patients without GA. Higher rates of all-cause hospitalizations (RR [95% CI]: 1.08 [1.03, 1.12]), outpatient visits (1.08 [1.05, 1.10]), other visits (1.14 [1.08, 1.21]), and falls with head injuries (1.24 [1.05, 1.45]) were observed in patients with GA vs without GA (P<0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with GA + B had higher rates of all-cause and ophthalmic condition-related hospitalizations, ER visits, and other visits PPY than patients with GA only (all P<0.05), with 2.88 (95% CI: 2.14, 3.86) times more ophthalmic condition-related hospitalizations, 1.74 (95% CI: 1.14, 2.66) times more ophthalmic condition-related ER visits, and 2.41 (95% CI: 1.90, 3.05) times more ophthalmic condition-related other visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to controls, patients with GA also had an increased risk for hospitalization (RR 1.18–1.27), emergency department visits (RR 1.18–1.21), nursing home or assisted living admissions (RR 1.06–1.28), and outpatient visits (RR 1.05–1.08).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Clinformatics®, MarketScan, and PharMetrics datasets included 44,591, 9470, and 27,428 patients with GA, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no statistically significant difference between the 2 cohorts in the use of health care resources like inpatient stays, length of stay, ED visits, and telehealth services, except for higher number of outpatient visits in individuals with GA (mean [SD] = 18.3 [15.9] vs 16.7 [15.9]; GA vs non-GA cohort, respectively, P < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Geographic atrophy-specific outpatient visits and costs by severity: United States commercial claims
“A total of 28,773 GA cases were identified (mean age = 68.7; 58.5% female), of which 24% and 76% had unilateral and bilateral GA, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with greater baseline severity in the bilateral group had a significantly higher number of outpatient (OP) visits per year (1.98 EI AMD; 2.57 for GAwoSF; 2.63 for GAwSF).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, higher payer-related costs were seen in patients with bilateral GAwSF compared to bilateral EI AMD (mean [SD] $280 [$325]; $198 [$262]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, however, the actual costs were not large, ranging from $56–$110, given that these were disease-specific, and not all-cause, costs and thus, we would be capturing outpatient visits that do not require any active therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Total cost of care by visual acuity impairment: IRIS Registry linked to claims
“A total of 5827 patients were included in the closed-claims cohorts. By year 2, VA impairment was associated with an increase of more than 26% in total cost of care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In models through year 2, mild (20/25 to 20/40) and moderate (20/50 to 20/100) VA impairment were associated with a more than 30% increase in total cost of care; moderately severe VA impairment (20/125 to 20/200) was associated with a 26% increase in cost; and severe VA impairment (worse than 20/200) was associated with a 43% increase in cost (mild: adjusted cost ratio, 1.31 [95% CI, 0.98-1.74, P = .061); moderate: adjusted cost ratio, 1.37 [95% CI, 1.00-1.86], P = .045; moderately severe: adjusted cost ratio, 1.26 [95% CI, 0.86-1.83], P = .237; severe: adjusted cost ratio, 1.43 [95% CI, 0.88-2.34], P = .127).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-year all-cause costs and indirect costs: systematic literature review
“In a US retrospective study (N = 14,421), mean total first-year cost postdiagnosis per patient with GA to the health-care system was US $11,672 (Figure 1).34” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs presented in the included studies were converted, as applicable, to US dollars (USD) in the reported cost year; all costs were then inflated to 2020 USD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our review identified only 7 studies with heterogeneous methodologies reporting on resource utilization and costs associated with GA, and no economic models. We identified only one study, published in 2005, on indirect costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Societal cost of illness per person with geographic atrophy: United States estimate
| Cost category, United States, per person per year | Geographic atrophy, € (% of total) | Neovascular AMD, € (% of total) |
|---|---|---|
| Direct medical cost | “327 (0.8)”View highlighted excerpt for this quote | “9073 (18.5)”View highlighted excerpt for this quote |
| Indirect medical cost | “12 744 (32.5)”View highlighted excerpt for this quote | “3385 (7.0)”View highlighted excerpt for this quote |
| Well-being cost | “11 948 (30.4)”View highlighted excerpt for this quote | “13 702 (28.0)”View highlighted excerpt for this quote |
| Productivity cost | “14 232 (36.3)”View highlighted excerpt for this quote | “22 714 (46.5)”View highlighted excerpt for this quote |
| Total | “39 251 (100)”View highlighted excerpt for this quote | “48 874 (100)”View highlighted excerpt for this quote |
| Financial costs | “27 303 (69.6)”View highlighted excerpt for this quote | “35 172 (72)”View highlighted excerpt for this quote |
“Estimated per-annum total costs attributable to late-stage AMD were €449.5 million ($512.5 million) in Bulgaria, €7.6 billion ($8.6 billion) in Germany, and €43.2 billion ($49.4 billion) in the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The financial costs incurred due to nAMD amounted to €17.2 billion ($19.7 billion) and totaled €13.4 billion ($15.3 billion) for GA (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We observed higher direct medical costs for nAMD compared with GA across all countries. This finding is reasonable given the fact that several treatment options were available for nAMD but not for GA at the time of conducting this research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First, the patient survey data were based on a relatively small sample of participants in each country; therefore, the model may have over- or underestimated certain cost parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Direct and indirect ophthalmic resource use and costs: United Kingdom, Germany, Ireland, and Canada
“In the 24 months before study inclusion, 85.4% of patients with GA had an ophthalmology-related visit, 81.5% had at least one test or procedure (averaging 8.2–9.6 tests/procedures per year), and 10% accessed home health care services.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The associated mean annual costs for direct ophthalmological resource per patient amounted to €1772, comprising €188 for ophthalmology-related visits, €1071 for tests/procedures, €116 for drugs or other treatments, €319 for home health care services, €63 for vision-related equipment, and €14 for eye rehabilitation services (Table S6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The associated mean annual costs for indirect ophthalmological resource use per patient were €234, comprising €177 for GP visits, €12 for emergency department visits, €39 for inpatient admissions, and €7 for outpatient admissions (Table S6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annualized average total cost (direct and indirect ophthalmic HCRU) was €2006 per patient with GA, with direct health care costs accounting for most of these costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs of vision loss and blindness in the United States: all causes
“We estimated an economic burden of VL of $134.2 billion: $98.7 billion in direct costs and $35.5 billion in indirect costs. The largest burden components were NH ($41.8 billion), other medical care services ($30.9 billion), and reduced labor force participation ($16.2 billion), all of which accounted for 66% of the total. Those with VL incurred $16 838 per year in incremental burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Informal care was the largest burden component for people 0 to 18 years of age, reduced labor force participation was the largest burden component for people 19 to 64 years of age, and NH costs were the largest burden component for people 65 years of age or older.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Geographic atrophy secondary to age-related macular degeneration on families
Caregiver time, transportation, and household tasks: United States caregiver survey
“Eighty-three percent (83%) of caregivers reported having to drive patients to their eye appointments for GA and 76% reported having to drive patients to other medical appointments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers reported spending a median time of 10 (interquartile range: 5–25) hours per week on household tasks that the patients would have been able to perform independently if not for their visual impairment due to GA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers reported having provided support for a mean (SD) of 3.3 (4.7) years to the patient with GA they cared for, and 81% of caregivers reported living with the person they cared for.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver employment and out-of-pocket spending: United States caregiver survey
“A relatively high proportion of caregivers (41%) had a change in their employment status after becoming a caregiver, with 50% of them unable to work due to caregiving; 29% reported working fewer hours, and 12% retired early.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients and caregivers reported using their own money to purchase products to assist the patient with GA, including items such as extra lighting (63% and 52%, respectively), eyeglasses (72% and 51%, respectively) or devices to assist with reading (64% and 50%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients and caregivers also reported significant financial burden, with 44% of patients and 37% of caregivers being concerned or very concerned about the effect of GA on their finances in the future.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden scores and their association with patient vision-related quality of life
“Regarding caregivers, mean (SD) ZBI total score was 24.8 (18.7) on a scale ranging from 0 to 88, in which higher score indicates more severe burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, Spearman rank-order correlation coefficients between NEI VFQ-39 subscale and composite scores and ZBI total score ranged from −0.63 to −0.21, indicating a correlation between vision-related QoL of the patient and the caregiver’s burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver share of productivity costs: United States cost-of-illness estimate for late AMD
“In GA, 88% of the total cost incurred due to the loss of productivity resulted from the impact on patients, while the remaining 12% of the cost was attributable to the impact on caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, in the US, particularly for GA, a sizeable proportion of productivity cost (12%) was attributed to caregivers’ loss of productivity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Productivity costs accounted for the loss of productivity and employment changes for patients and caregivers. Parameters included patient job loss, patient job reduction, caregiver job reduction due to caregiving responsibilities, caregiver job reduction due to providing transport to eye health care appointments, and caregiver loss of leisure time due to providing transport.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs to patients and caregivers: systematic literature review
“Patients and caregivers incur out-of-pocket costs; for US patients, these included vision aids such as magnifying systems, flashlights, or talking watches. Caregivers usually provided transportation and helped with household chores.5 A US retrospective cohort study of administrative claims data (n = 14,421) from 2015 to 2018 determined the mean cost to the patient with GA to be $2863 (adjusted to 2020 USD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, very little information was identified on the humanistic effect on caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Travel companions and informal care
“Most patients with GA reported regularly traveling with a partner or friend.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is clear that support, whether through informal or structured care, is vital to the wellbeing of people with GA. Despite this, the general public are often unaware of care work, which may result in this integral role being undervalued and under acknowledged.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Medicare national average office-based payment for retinal imaging, 2025 and 2026
| CPT code | 2025 non-facility total RVUs | 2026 non-facility total RVUs | 2025 non-facility pay | 2026 non-facility pay | Change in non-facility pay, 2025 to 2026 |
|---|---|---|---|---|---|
| 92134 (OCT, retina) | “0.97” | “0.98” | “$31.38” | “$32.73” | “4.32%” |
| 92137 (OCT angiography, retina) | “1.76” | “1.79” | “$56.93” | “$59.79” | “5.02%” |
| 92250 (fundus photography) | “1.1” | “1.11” | “$35.58” | “$37.07” | “4.20%” |
| 92235 (fluorescein angiography) | “4.72” | “4.86” | “$152.68” | “$162.33” | “6.32%” |
Coding of multimodal imaging for geographic atrophy
Diagnostic imaging at the index diagnosis: Medicare Advantage claims
| Diagnostic procedure received on index date | Participants with GA, n (%) |
|---|---|
| Any of the procedures below | “6,968 (73.3)”View highlighted excerpt for this quote |
| OCT | “5,042 (53.0)”View highlighted excerpt for this quote |
| Fundus photography | “2,039 (21.4)”View highlighted excerpt for this quote |
| Fluorescein angiography | “600 (6.3)”View highlighted excerpt for this quote |
| Fluorescein and indocyanine-green angiography at the same time | “97 (1.0)”View highlighted excerpt for this quote |
“The specialty of the GA diagnosing provider was determined using National Provider Identifiers, and diagnostic imaging procedures used for confirming GA diagnosis were identified using Current Procedural Terminology codes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals with GA, initial diagnosis was primarily by an ophthalmologist (58.6%) followed by an optometrist (30.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic tests as the main driver of direct ophthalmic costs
“A variety of tests were conducted at GA diagnosis; the most common ones (used in the 98 patients initially diagnosed with bilateral GA) were distance VA (86.7%), dilated eye examination (82.7%), optical coherence tomography (OCT; 81.6%), intraocular pressure (IOP; 67.3%), and fundus autofluorescence (FAF; 44.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similar to the UK cohort study, direct HCRU in our study accounted for the majority of the mean annual total costs (88%; €1772), with diagnostics tests and procedures being the main driver (€1071 per patient).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Antioxidant vitamin and mineral supplementation
Guideline recommendation for antioxidant supplementation in intermediate and advanced AMD
AREDS formulation and progression to advanced AMD
“Participants were randomly assigned to receive daily oral tablets containing: (1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg); (2) zinc, 80 mg, as zinc oxide and copper, 2 mg, as cupric oxide; (3) antioxidants plus zinc; or (4) placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Average follow-up of the 3640 enrolled study participants, aged 55–80 years, was 6.3 years, with 2.4% lost to follow-up. Comparison with placebo demonstrated a statistically significant odds reduction for the development of advanced AMD with antioxidants plus zinc (odds ratio [OR], 0.72; 99% confidence interval [CI], 0.52–0.98).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The only statistically significant reduction in rates of at least moderate visual acuity loss occurred in persons assigned to receive antioxidants plus zinc (OR, 0.73; 99% CI, 0.54–0.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Those with extensive intermediate size drusen, at least 1 large druse, noncentral geographic atrophy in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye, and without contraindications such as smoking, should consider taking a supplement of antioxidants plus zinc such as that used in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AREDS2 formulation: lutein and zeaxanthin in place of beta carotene
“Median follow-up was 5 years, with 1940 study eyes (1608 participants) progressing to advanced AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Comparison with placebo in the primary analyses demonstrated no statistically significant reduction in progression to advanced AMD (hazard ratio [HR], 0.90 [98.7% CI, 0.76-1.07]; P = .12 for lutein + zeaxanthin; 0.97 [98.7% CI, 0.82-1.16]; P = .70 for DHA + EPA; 0.89 [98.7% CI, 0.75-1.06]; P = .10 for lutein + zeaxanthin and DHA + EPA).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More lung cancers were noted in the beta carotene vs no beta carotene group (23 [2.0%] vs 11 [0.9%], nominal P = .04), mostly in former smokers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, because of potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Supplementation and geographic atrophy progression toward the fovea: post hoc analysis of AREDS and AREDS2
“Post hoc analysis of the Age-Related Eye Diseases Study (AREDS) and AREDS2, multi-center randomized placebo-controlled trials of oral micronutrient supplementation, each with 2×2 factorial design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“392 eyes (318 participants) with GA in AREDS; 1210 eyes (891 participants) with GA in AREDS2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In AREDS eyes with non-central GA (n=208), proximity-based progression towards the central macula was significantly slower with randomization to antioxidants versus none, at 50.7 μm/year (95% CI 38.0–63.4 μm/year) versus 72.9 μm/year (95% CI 61.3–84.5 μm/year; p=0.012), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In AREDS2 eyes with non-central GA, in participants assigned to AREDS antioxidants without β-carotene (n=325 eyes), proximity-based progression was significantly slower with randomization to lutein/zeaxanthin versus none, at 80.1 μm/year (95% CI 60.9–99.3 μm/year) versus 114.4 μm/year (95% CI 96.2–132.7 μm/year; p=0.011), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In AREDS eyes with any GA (n=392), area-based progression was not significantly different with randomization to antioxidants versus none (p=0.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oral micronutrient supplementation slowed GA progression towards the central macula, likely by augmenting the natural phenomenon of foveal sparing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Photobiomodulation
FDA De Novo authorization: indications for use
Treatment regimen
LIGHTSITE III: best-corrected visual acuity in the FDA review
LIGHTSITE III: new-onset and existing geographic atrophy at Month 13
“A very small number of eyes presented with noncenter involving GA at baseline (PBM, n = 6; Sham, n = 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using FAF analysis, a numerical trend showed an increase in GA lesion area in Sham (1.48, SE 0.94; SD 1.62) compared with PBM-treated eyes (1.16, SE 0.66; SD 1.32, P = 0.75) at Month 13 (change from baseline; Table 2; Figure 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The occurrence of new GA was significantly higher in the Sham versus PBM group (P = 0.024, Fisher exact test, odds ratio 9.4) (Table 2; Figure 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline appraisal and evidence grade
Complement c3 inhibitors
Pegcetacoplan: mechanism and FDA approval
“On February 17, 2023, pegcetacoplan 15 mg (Syfovre, Apellis Pharmaceuticals) was approved by the US Food and Drug Administration (FDA) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pegcetacoplan is a polyethylene-glycolylated (PEGylated) peptide that blocks complement factor C3, which has been implicated in the development of both the exudative and advanced atrophic forms of AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pegcetacoplan: indication, dosage, and contraindications
Pegcetacoplan: retinal vasculitis and retinal vascular occlusion warning
Pegcetacoplan: neovascular AMD, intraocular inflammation, and ischemic optic neuropathy
OAKS and DERBY: design
OAKS and DERBY: GA lesion growth from baseline to month 24
| Study and group | Rate of GA lesion area growth (mm2), slope (SE) | Difference (95% CI) in slope from sham pooled | Percent difference from sham pooled |
|---|---|---|---|
| OAKS, pegcetacoplan monthly | “3.11 (0.148)” | “−0.87”“(−1.27 to −0.47)” | “−21.9%” |
| OAKS, pegcetacoplan every other month | “3.26 (0.134)” | “−0.72”“(−1.10 to −0.33)” | “−18.1%” |
| OAKS, sham pooled | “3.98 (0.143)” | “NA” | “NA” |
| DERBY, pegcetacoplan monthly | “3.28 (0.125)” | “−0.73”“(−1.14 to −0.31)” | “−18.1%” |
| DERBY, pegcetacoplan every other month | “3.31 (0.129)” | “−0.70”“(−1.11 to −0.28)” | “−17.4%” |
| DERBY, sham pooled | “4.00 (0.169)” | “NA” | “NA” |
OAKS and DERBY: primary endpoint at month 12 and visual function endpoints
“The primary endpoint was the change from baseline to month 12 in the total area of geographic atrophy lesions in the study eye based on fundus autofluorescence imaging” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In DERBY, pegcetacoplan monthly and pegcetacoplan every other month slowed geographic atrophy lesion growth, although it did not reach significance, by 12%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were no differences in key secondary visual function endpoints at 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
OAKS and DERBY: guideline summary of lesion growth reductions
GALE open-label extension: up to 36 months of pegcetacoplan
“Through the first 12 months of GALE, 92.0% (727/790) patient retention was observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all eyes, including eyes with nonsubfoveal and subfoveal GA, pegcetacoplan reduced the mean rate of change in GA area up to 32% versus projected sham.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events included 33 (4.5%) eyes with exudative AMD, 15 (1.9%) intraocular inflammation (classified as mild or moderate in severity), 1 (0.1%) ischemic optic neuropathy, and 1 (0.1%) infectious endophthalmitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No events of vasculitis were reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GALE open-label extension: up to 48 months, early versus delayed treatment
“The delayed treatment group included sham-observed eyes from OAKS and DERBY which crossed over at 24 months to receive pegcetacoplan treatment for 24 months in the GALE OLE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the overall population, 48 continuous months of pegcetacoplan treatment reduced GA area growth rate by up to 24% compared with projected sham, translating to 1.88 mm2 of retinal tissue.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“GALE safety data were consistent with the findings of the OAKS and DERBY studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pegcetacoplan: postmarketing retinal vasculitis case series
“Fourteen eyes of 13 patients were confirmed to have retinal vasculitis by review of imaging studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All cases occurred after the first pegcetacoplan injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Occlusive retinal vasculopathy was confirmed in 11 eyes (79%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eight eyes (57%) had more than a 3-line decrease in VA, and 6 eyes (43%) had more than a 6-line decrease in VA from baseline to the final follow-up, including 2 eyes that were enucleated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement c5 inhibitors
Avacincaptad pegol: indication, dosage, and contraindications
Avacincaptad pegol: neovascular AMD and intraocular pressure warnings
GATHER1 and GATHER2: design
GATHER1 and GATHER2: GA growth with monthly dosing
| Study and time point | Avacincaptad pegol, N | Sham, N | GA rate of growth, avacincaptad pegol (mm2/year) | GA rate of growth, sham (mm2/year) | Difference (95% CI) (mm2/year) | Difference % | p value |
|---|---|---|---|---|---|---|---|
| GATHER1, month 12 | “N=67” | “N=110” | “1.22” | “1.89” | “0.67 (0.21-1.13)” | “35%” | “<0.01” |
| GATHER2, month 12 | “N=225” | “N=222” | “1.75” | “2.12” | “0.38 (0.12-0.63)” | “18%” | “<0.01” |
| GATHER2, month 24 (monthly in both years) | “N=96” | “N=203” | “2.23” | “2.59” | “0.36 (0.07 – 0.66)” | “14%” | “0.0165” |
GATHER1: phase 2/3 primary endpoint
“A total of 286 participants with GA secondary to AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The reduction in the mean rate of GA growth (square root transformation) over 12 months was 27.4% (P = 0.0072) for the avacincaptad pegol 2 mg cohort and 27.8% (P = 0.0051) for the avacincaptad pegol 4 mg cohort compared with their corresponding sham cohorts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GATHER2: 12-month primary endpoint and safety
“To be eligible, patients had to be aged 50 years or older with non-centrepoint-involving geographic atrophy and best corrected visual acuity between 20/25 and 20/320 in the study eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between June 22, 2020, and July 23, 2021, 1422 patients were screened for eligibility, of whom 448 were enrolled and randomly assigned to avacincaptad pegol 2 mg (n=225) or sham (n=223).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“representing a 14% difference between the avacincaptad pegol 2 mg group and the sham group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were no endophthalmitis, intraocular inflammation, or ischaemic optic neuropathy events over 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To month 12, macular neovascularisation in the study eye occurred in 15 (7%) patients in the avacincaptad pegol 2 mg group and nine (4%) in the sham group, with exudative macular neovascularisation occurring in 11 (5%) in the avacincaptad pegol 2 mg group and seven (3%) in the sham group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GATHER2: two-year results
“Overall, 175 and 184 patients in the ACP and sham group completed the study at year 2, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From baseline to year 2, the mean rate of GA area growth was 4.46 mm2 (standard error [SE], 0.25 mm2) with ACP EM and 5.18 mm2 (SE, 0.17 mm2) with sham, a difference in growth of 0.724 mm2 (95% confidence interval [CI], 0.133-1.315 mm2; P = 0.0165), representing a 14% difference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of choroidal neovascularization (study eye) was 11.6% with ACP (all treated) versus 9.0% with sham over 2 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No events of retinal vasculitis, ischemic optic neuropathy, or serious intraocular inflammation occurred over 2 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GATHER2: guideline summary of lesion growth reductions
GATHER1 and GATHER2: post hoc analysis of vision loss
“A post hoc analysis of 12-month data for pooled ACP 2 mg and sham groups is reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lower proportions of study eyes experienced ≥10-, ≥15-, or ≥20-BCVA letter loss from baseline over 12 months with ACP 2 mg (11.6%, 4.0%, and 1.6%, respectively) versus sham (14.1%, 7.6%, and 4.5%, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was a reduction in the risk of persistent loss of ≥15 BCVA ETDRS letters with ACP 2 mg (3.4%) versus sham (7.8%) through 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Vision rehabilitation
Referral for vision rehabilitation in AMD
Vision rehabilitation guideline: scope and referral criteria
Vision rehabilitation guideline: reading with central scotoma and eccentric viewing training
Limitations of current therapies
Summary: limitations of complement inhibitor therapy
Two intravitreal complement inhibitors are approved by the FDA for geographic atrophy: pegcetacoplan (C3 inhibitor), given every 25 to 60 days, and avacincaptad pegol (C5 inhibitor), given once monthly (approximately every 28 ± 7 days). Both reduced the growth of geographic atrophy lesions in sham-controlled phase 3 trials (pegcetacoplan by 22% monthly and 18% every other month at 24 months in OAKS; avacincaptad pegol by 14% in square-root-transformed growth at 12 months and by 14% at 24 months with monthly dosing in GATHER2). Neither improved visual function: the AAO Preferred Practice Pattern states that “There was no benefit for BCVA in the clinical trials for either pegcetacoplan or avacincaptad pegol”, and the 2023 Cochrane review of 10 randomized trials (4052 participants) found “no evidence that complement inhibition with any agent improves functional endpoints in advanced AMD”. The avacincaptad pegol finding of fewer eyes with persistent vision loss comes from a post hoc analysis of 12-month data.
Treatment requires indefinite intravitreal injections. In OAKS and DERBY, 21% to 31% of participants in the pegcetacoplan arms discontinued treatment before month 24. In a retrospective real-world cohort of eyes treated with pegcetacoplan or avacincaptad pegol, retention declined over the first 12 months, and pegcetacoplan treatment (hazard ratio 3.32), new neovascular AMD (odds ratio 3.02), and poor baseline visual acuity were associated with attrition.
Both products increase conversion to neovascular AMD: 12% with monthly and 7% with every-other-month pegcetacoplan against 3% with control by month 24, and 12% with avacincaptad pegol against 9% with sham over 24 months in GATHER2. Pegcetacoplan carries a warning for retinal vasculitis and/or retinal vascular occlusion, which may occur with the first dose and may cause severe vision loss. A postmarketing case series confirmed retinal vasculitis in 14 eyes of 13 patients, all after the first injection, with a more than 6-line loss of visual acuity in 6 eyes (43%); the guideline cites a postmarketing rate of 0.01% per injection. No retinal vasculitis was reported in the pivotal trials, which had no protocol for angiography in eyes with intraocular inflammation.
Neither product is authorized in the European Union. The European Medicines Agency confirmed its recommendation to refuse marketing authorisation for pegcetacoplan on 19 September 2024 because slowing lesion growth “did not lead to clinically meaningful benefits for patients”, and Astellas withdrew its application for avacincaptad pegol on 24 October 2024 after the Agency's provisional opinion that the product could not have been authorised. NICE suspended its appraisal of pegcetacoplan in February 2025, after the company reported that it did not receive marketing authorisation from the MHRA and has since discontinued it. The guideline notes that long-term, real-world data for both products are lacking.
No visual function benefit in the pivotal trials
Guideline position on monitoring, long-term data, and shared decision-making
Pooled effects of complement inhibitors on visual acuity, lesion growth, and adverse events
“Ten RCTs with 4052 participants and eyes with GA were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For 242 participants in one study, pegcetacoplan probably did not meaningfully change BCVA given monthly (+1.05 letters, 95% CI −2.71 to 4.81) or EOM (−1.42 letters, 95% CI −5.25 to 2.41), as supported by moderate‐certainty evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These reductions correspond to 19.2% and 14.8% versus sham, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a study of 260 participants with extrafoveal or juxtafoveal GA, monthly avacincaptad pegol probably did not result in a clinically meaningful change in BCVA at 2 mg (+1.39 letters, 95% CI −5.89 to 8.67) or 4 mg (−0.28 letters, 95% CI −8.74 to 8.18), based on moderate‐certainty evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, there is currently no evidence that complement inhibition with any agent improves functional endpoints in advanced AMD; further results from the phase 3 studies of pegcetacoplan and avacincaptad pegol are eagerly awaited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Progression to MNV or exudative AMD is a possible emergent adverse event of complement inhibition, requiring careful consideration should these agents be used clinically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intravitreal administration of complement inhibitors is probably associated with a small risk of endophthalmitis, which may be higher than that of other intravitreal therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient acceptability of injections conditional on functional benefit
“Intravitreal complement inhibitors injections (IVCIs) slowed progression of geographic atrophy (GA) lesions in several registration phase 3 trials although without benefit for prespecified secondary functional vision outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This cross-sectional study of 153 UK-based patients with GA, more than half found intravitreal injections for GA at least very acceptable, assuming treatment had vision functional benefits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment discontinuation in OAKS and DERBY
Real-world attrition on complement inhibitor therapy
“To identify characteristics of patients with geographic atrophy (GA) who received pegcetacoplan or avacincaptad pegol and discontinued treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment retention declined between 0 and 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline predictors of attrition were age older than 90 years (HR, 1.26; 95% CI, 1.03-1.55; P = .028), pegcetacoplan treatment (HR, 3.32; 95% CI, 2.92-3.76; P < .001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Significant predictors included new nAMD (OR, 3.02; 95% CI, 2.35-3.89; P < .001) and a loss of more than 5 ETDRS letters (OR, 1.36; 95% CI, 1.17-1.58; P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Poor baseline vision and development of new nAMD are associated with patient attrition, and the combination of nAMD and GA and treatment burden challenges patient retention.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
New-onset exudative AMD with pegcetacoplan in OAKS and DERBY
“New-onset exudative age-related macular degeneration was reported in 24 (11%), 16 (8%), and four (2%) patients in OAKS, and in 27 (13%), 12 (6%), and nine (4%) patients in DERBY receiving pegcetacoplan monthly, pegcetacoplan every other month, and sham, respectively, at 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Retinal vasculitis and intraocular inflammation after pegcetacoplan
“There were no reported cases of retinal vasculitis or occlusive retinal vasculopathy in the clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, however, there was no defined protocol in these studies to obtain angiography in cases of intraocular inflammation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Voluntary reporting of adverse events is inherently subject to underreporting, and it is possible that some cases of retinal vasculitis have not been reported to the ReST Committee, the company, or the FDA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
European Medicines Agency refusal of pegcetacoplan
Withdrawal of the European marketing authorisation application for avacincaptad pegol
Discontinued NICE appraisal of pegcetacoplan
Place in treatment, anticipated use, and care setting
Summary: anticipated use and care setting
Vonaprument is not approved for any use. In the phase 3 ARCHER II trial it is given as 5.0 mg per eye by monthly intravitreal injection, which places its anticipated use among physician-administered intravitreal therapies, the same route and setting as the two approved complement inhibitors for geographic atrophy, pegcetacoplan and avacincaptad pegol. The AAO Preferred Practice Pattern states that the ophthalmologist should administer all treatment and anti-VEGF injections for AMD. A U.S. expert panel recommends nonurgent referral to a retina specialist for any suspected geographic atrophy and notes that current anti-complement therapy requires “office visits every 1 to 2 months”.
In a footnote that begins “Based on market reports”, the sponsor estimates that approximately 75,000 U.S. patients are actively treated with available therapies, about 10% of the 800,000 people diagnosed with geographic atrophy or under the care of retina specialists and about 5% of an estimated 1.5 million U.S. people with geographic atrophy. Medicare Part B fee-for-service data for 2025 record 32,021 beneficiaries with 168,366 claims for pegcetacoplan and 27,497 beneficiaries with 140,741 claims for avacincaptad pegol, with total spending of about $451.1 million and $364.9 million. For the first quarter of 2026 the counts were 24,179 and 23,315 beneficiaries. No source states a planned price, distribution model, or position in a treatment sequence for vonaprument.
Investigational dose, frequency, and route
Provider and setting for intravitreal treatment of AMD
Referral to retina specialists and office visit frequency for approved complement inhibitors
“A nonurgent referral to a retina specialist is recommended for any suspected GA in one or both eyes, whereas a more urgent referral should be made for any patient with suspected neovascular AMD (nAMD)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To streamline care, patients may consider monitoring (or possibly even treatment) by their comprehensive ophthalmologist under the guidance of a retina specialist, which may help maintain compliance and overall treatment fidelity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current anti-complement therapy for GA requires treatment with office visits every 1 to 2 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Timing of referral to retina specialists must be optimized to consider the burden on patients and caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor estimate of the treated and untreated U.S. population
Medicare Part B use of approved complement inhibitors for geographic atrophy
Heterogeneity of treatment effect
Lesion location: foveal and non-foveal subgroups, stratified combined analysis (topline data)
Lesion location: final data with nominal p values within each subgroup
| Lesion location | Sham | Vonaprument every other month | Vonaprument every month |
|---|---|---|---|
| Foveal, participants with loss | “25.0%”“11/44” | “16.3%”“8/49” | “5.9%”“3/51” |
| Foveal, nominal p value versus sham | “---” | “.3003” | “.0088” |
| Non-foveal, participants with loss | “17.8%”“8/45” | “2.3%”“1/43” | “5.3%”“2/38” |
| Non-foveal, nominal p value versus sham | “---” | “.0168” | “.0810” |
Subfoveal retinal pigment epithelium lesions: post hoc analysis
“76% Risk Reduction Vonaprument EM” (opens the source at this quote in a new tab)
“HR (CI) = 0.242 (0.067 to 0.881); Nominal p = .0204*” (opens the source at this quote in a new tab)
“41% Risk Reduction Vonaprument EOM” (opens the source at this quote in a new tab)
“HR (CI) = 0.504 (0.225 to 1.555); Nominal p = .2784” (opens the source at this quote in a new tab)
Baseline low-luminance visual deficit: healthier and less healthy retina, stratified combined analysis (topline data)
| Baseline LLVD | Sham | Vonaprument every month | Vonaprument every other month | Vonaprument pooled |
|---|---|---|---|---|
| Below 30 (healthier) | “16.9%”“(10/59)” | “0.0%”“(0/56)” | “6.3%”“(3/48)” | “2.9%”“(3/104)” |
| 30 or higher (less healthy) | “30.8%”“(8/26)” | “16.1%”“(5/31)” | “16.3%”“(7/43)” | “16.2%”“(12/74)” |
| Stratified p value versus sham | “--” | “0.0016” | “0.029” | “0.0009” |
Less advanced disease: low-luminance deficit, lesion size, and ellipsoid zone integrity (additional analyses)
Baseline characteristics associated with confirmed loss of 15 or more letters
Care management intervention strategies
Monitoring for conversion to neovascular AMD during complement inhibitor therapy
“If an eye develops nAMD during GA treatment, nAMD treatment will need to be initiated if there are signs of exudation in the macula.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combined GA and nAMD treatment is both feasible and safe based on pivotal clinical trials, but injections may need to be provided either on different clinical visits or separated by approximately 30 min if performed on the same day to minimize the risk of excessive intraocular pressure elevation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-monitoring and electronic home monitoring
Follow-up visits: history and examination
“Changes in medications and nutritional supplements” (opens the source at this quote in a new tab)
“Visual acuity at distance with correction” (opens the source at this quote in a new tab)
“As with many diseases, the severity and rate of progression will vary from patient to patient. Therefore, adjustments to follow-up frequency should be considered depending on the identification of signs of increased risk, such as advanced age, family history, smoking history, and whether the patient is monocular.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient education and shared decision-making
“Additionally, the physician should educate the patient with regard to GA progression and treatment expectations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, the treating physician should educate patients on symptoms that may signify occurrence of adverse events, such as pain, new visual changes, or new floaters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment selection and discontinuation for approved complement inhibitors
“In general, treatment decisions are influenced by patient symptoms, visual acuity, age, fellow-eye status, and ocular comorbidities, as well as the discretion of the physician and patient to conduct a comprehensive personalized risk-benefit assessment that is guided by a general evidence-based treatment algorithm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several circumstances may warrant discontinuation of GA treatment, such as the occurrence of severe adverse events including endophthalmitis, ischemic optic neuropathy, sustained elevation of intraocular pressure, and significant, nontransient intraocular inflammation, especially if associated with any retinal vasculitis or occlusive vasculitis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, severe central vision loss may represent a scenario where ongoing treatment risks or burdens may not significantly outweigh any potential benefits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.